Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RGT 61159

Next Previous
Drug Profile

RGT 61159

Alternative Names: RGT-61159

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rgenta Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c-myb expression inhibitors; RNA splicing modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenoid cystic carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adenoid cystic carcinoma; Colorectal cancer
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 19 Sep 2025 RGT 61159 receives Orphan Drug status for Adenoid cystic carcinoma in USA
  • 12 Jun 2025 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia released by Rgenta Therapeutics
  • 25 Apr 2025 Pharmacodynamics data from preclinical trial in Acute myeloid leukemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top